218 related articles for article (PubMed ID: 16980216)
1. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting.
Veale DJ; Fearon U
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):941-7. PubMed ID: 16980216
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritis.
Schoettler N; Brahn E
Curr Opin Investig Drugs; 2009 May; 10(5):425-33. PubMed ID: 19431075
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures.
Fearon U; Mullan R; Markham T; Connolly M; Sullivan S; Poole AR; FitzGerald O; Bresnihan B; Veale DJ
Arthritis Rheum; 2006 Oct; 54(10):3152-62. PubMed ID: 17009243
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
Forooghian F; Das B
Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
[TBL] [Abstract][Full Text] [Related]
6. [The role of angiogenesis in rheumatoid arthritis].
Pałgan K
Postepy Hig Med Dosw; 2000; 54(6):855-65. PubMed ID: 11227381
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic function of tocotrienol.
Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets.
Vizán P; Sánchez-Tena S; Alcarraz-Vizán G; Soler M; Messeguer R; Pujol MD; Lee WN; Cascante M
Carcinogenesis; 2009 Jun; 30(6):946-52. PubMed ID: 19369582
[TBL] [Abstract][Full Text] [Related]
9. Targeting rheumatoid tenosynovial angiogenesis with cytokine inhibitors.
Jain A; Kiriakidis S; Brennan F; Sandison A; Paleolog E; Nanchahal J
Clin Orthop Relat Res; 2006 May; 446():268-77. PubMed ID: 16456308
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis.
Kim WU; Kwok SK; Hong KH; Yoo SA; Kong JS; Choe J; Cho CS
Arthritis Res Ther; 2007; 9(2):R42. PubMed ID: 17459170
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis.
Malemud CJ
Clin Chim Acta; 2007 Jan; 375(1-2):10-9. PubMed ID: 16893535
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
13. [Targeting angiogenesis in oncology].
Fayette J; Soria JC; Armand JP
Pathol Biol (Paris); 2006 May; 54(4):199-205. PubMed ID: 16753494
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis: a therapeutic target in arthritis.
Walsh DA; Haywood L
Curr Opin Investig Drugs; 2001 Aug; 2(8):1054-63. PubMed ID: 11892913
[TBL] [Abstract][Full Text] [Related]
15. Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection.
Hashimoto A; Tarner IH; Bohle RM; Gaumann A; Manetti M; Distler O; Steinmeyer J; Ulfgren AK; Schulz A; Gay S; Müller-Ladner U; Neumann E
Arthritis Rheum; 2007 Apr; 56(4):1094-105. PubMed ID: 17393418
[TBL] [Abstract][Full Text] [Related]
16. Human inflammatory synovial fibroblasts induce enhanced myeloid cell recruitment and angiogenesis through a hypoxia-inducible transcription factor 1alpha/vascular endothelial growth factor-mediated pathway in immunodeficient mice.
del Rey MJ; Izquierdo E; Caja S; Usategui A; Santiago B; Galindo M; Pablos JL
Arthritis Rheum; 2009 Oct; 60(10):2926-34. PubMed ID: 19790065
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
18. Macrophages and their products in rheumatoid arthritis.
Szekanecz Z; Koch AE
Curr Opin Rheumatol; 2007 May; 19(3):289-95. PubMed ID: 17414958
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance.
Szekanecz Z; Szegedi G; Koch AE
J Investig Med; 1998 Feb; 46(2):27-41. PubMed ID: 9549225
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases.
Billington DC
Drug Des Discov; 1991 Nov; 8(1):3-35. PubMed ID: 1725722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
